ELREXFIO (elranatamab) for Multiple Myeloma: Patient Story + Doctor Explains
12:26
YouTubeInternational Myeloma Foundation
ELREXFIO (elranatamab) for Multiple Myeloma: Patient Story + Doctor Explains
What is a bispecific antibody, and how can it help in relapsed or refractory multiple myeloma? In this video, health professionals explain how bispecific therapies work, what to expect during treatment, and why monitoring labs and side effects matters—alongside a real patient story about living with multiple myeloma and regaining the freedom ...
807 views1 month ago
Related Products
Cevostamab and Elranatamab
Elranatamab Affinity
Elranatamab Ash
#Elranatamab Clinical Trial
Clinical Insights on the Efficacy and Safety of Bispecific Antibodies in Multiple Myeloma | AJMC
Clinical Insights on the Efficacy and Safety of Bispecific Antibodies in Multiple Myeloma | AJMC
ajmc.com1 month ago
Comparing Teclistamab, Elranatamab, and Linvoseltamab in MM: Response Rates, Toxicities, and Infection Risk
Comparing Teclistamab, Elranatamab, and Linvoseltamab in MM: Response Rates, Toxicities, and Infection Risk
vumedi.com4 months ago
Top videos
Dr Mohty on the Real-World Efficacy of Elranatamab in R/R Multiple Myeloma | OncLive
1:59
Dr Mohty on the Real-World Efficacy of Elranatamab in R/R Multiple Myeloma | OncLive
onclive.com
1 week ago
Dr Mohty on the Implications of Real-World Efficacy With Elranatamab in R/R Myeloma | OncLive
Dr Mohty on the Implications of Real-World Efficacy With Elranatamab in R/R Myeloma | OncLive
onclive.com
Jul 2, 2024
Elranatamab (ELREXFIO) - a BCMA x CD3 Bispecific Antibody for Multiple Myeloma
27:16
Elranatamab (ELREXFIO) - a BCMA x CD3 Bispecific Antibody for Multiple Myeloma
YouTubeHealthTree University for
2.2K viewsFeb 6, 2024
Elranatamab Side Effects
L'Elranatamab de Pfizer reçoit la désignation de thérapie révolutionnaire de la FDA pour le myélome multiple récidivant ou réfractaire.
L'Elranatamab de Pfizer reçoit la désignation de thérapie révolutionnaire de la FDA pour le myélome multiple récidivant ou réfractaire.
zonebourse.com
Nov 3, 2022
Pfizer's Elranatamab Granted FDA Breakthrough Therapy Designation for Relapsed or Refractory Multiple Myeloma
Pfizer's Elranatamab Granted FDA Breakthrough Therapy Designation for Relapsed or Refractory Multiple Myeloma
marketscreener.com
Nov 3, 2022
Dr Mohty on Extended Follow-up Data from MagnetisMM-3 With Elranatamab in R/R Myeloma | OncLive
Dr Mohty on Extended Follow-up Data from MagnetisMM-3 With Elranatamab in R/R Myeloma | OncLive
onclive.com
Jun 10, 2023
Dr Mohty on the Real-World Efficacy of Elranatamab in R/R Multiple Myeloma | OncLive
1:59
Dr Mohty on the Real-World Efficacy of Elranatamab in R/R Multiple My…
1 week ago
onclive.com
Dr Mohty on the Implications of Real-World Efficacy With Elranatamab in R/R Myeloma | OncLive
Dr Mohty on the Implications of Real-World Efficacy With Elranata…
Jul 2, 2024
onclive.com
Elranatamab (ELREXFIO) - a BCMA x CD3 Bispecific Antibody for Multiple Myeloma
27:16
Elranatamab (ELREXFIO) - a BCMA x CD3 Bispecific Antibody for Mult…
2.2K viewsFeb 6, 2024
YouTubeHealthTree University for Multiple Myeloma
Clinical Insights on the Efficacy and Safety of Bispecific Antibodies in Multiple Myeloma | AJMC
Clinical Insights on the Efficacy and Safety of Bispecific Antibodies in …
1 month ago
ajmc.com
Talquetamab and Elranatamab: Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Talquetamab and Elranatamab: Bispecific Antibodies in Relapsed/…
Oct 20, 2023
targetedonc.com
Efficacy and safety of elranatamab BCMA-CD3 bispecific antibody, in patients with RRMM
7:06
Efficacy and safety of elranatamab BCMA-CD3 bispecific antibody, in …
1.1K viewsJun 14, 2021
YouTubeInternational Myeloma Foundation
L'Elranatamab de Pfizer reçoit la désignation de thérapie révolutionnaire de la FDA pour le myélome multiple récidivant ou réfractaire.
L'Elranatamab de Pfizer reçoit la désignation de thérapie révolution…
Nov 3, 2022
zonebourse.com
7:02
Elranatamab in Transplant-Ineligible Newly Diagnosed Multiple Myelom…
401 views8 months ago
YouTubeInternational Myeloma Foundation
Pfizer's Elranatamab Granted FDA Breakthrough Therapy Designatio…
Nov 3, 2022
marketscreener.com
1:45
Using the available repertoire of bispecific antibodies for treating …
104 viewsFeb 26, 2024
YouTubeVJHemOnc – Video Journal of Hematology & H…
Talquetamab, Cevostamab and Elranatamab in RRMM | OncLive
Aug 4, 2022
onclive.com
4:39
What is the clinical experience with elranatamab for the treatment of …
303 viewsFeb 25, 2025
YouTubeMultiple Myeloma Hub
7:11
MagnetisMM-3: Long Term Efficacy & Safety of Less Frequent Elranat…
573 views1 year ago
YouTubeInternational Myeloma Foundation
Dr Mohty on Extended Follow-up Data from MagnetisMM-3 With Elra…
Jun 10, 2023
onclive.com
9:39
Tocilizumab's Role in Protecting Multiple Myeloma Patients on Bisp…
467 viewsJan 21, 2025
YouTubeInternational Myeloma Foundation
4:17
Evaluating the safety and efficacy of elranatamab in multiple myeloma
399 viewsJan 23, 2023
YouTubeVJHemOnc – Video Journal of Hematology & H…
1:47
What is the clinical experience with elranatamab for the treatment of M…
715 views9 months ago
YouTubeMultiple Myeloma Hub
7:04
Safety and efficacy of elranatamab in RRMM & prior BCMA therapies: …
324 viewsJul 13, 2023
YouTubeInternational Myeloma Foundation
3:59
Real-World Evidence and Selecting Optimal Bispecifics in Multiple My…
Feb 5, 2024
onclive.com
1:49
The benefit of bispecific antibodies & CAR-T therapy in triple class-ex…
122 viewsJul 10, 2023
YouTubeVJHemOnc – Video Journal of Hematology & H…
Pfizer : désignation 'Fast Track' de la FDA pour elranatamab
Feb 17, 2021
zonebourse.com
1:41
Real-world efficacy & safety of elranatamab in R/R myeloma: an I…
50 views1 month ago
YouTubeVJHemOnc – Video Journal of Hematology & H…
2:47
MagnestisMM-1: elranatamab alone or with immunomodulatory agent…
131 viewsJul 7, 2022
YouTubeVJHemOnc – Video Journal of Hematology & H…
3:34
Exciting results for BCMA/CD3 bispecific elranatamab (PF-3135) i…
701 viewsJan 24, 2020
YouTubeVJHemOnc – Video Journal of Hematology & H…
7:25
Promising Results with Elranatamab + Iberdomide from MagnetisMM-30…
120 views2 months ago
YouTubeHealthTree University for Multiple Myeloma
Comparing Teclistamab, Elranatamab, and Linvoseltamab i…
4 months ago
vumedi.com
56:35
Elranatamab: How it works, how it's being used, and how it compares t…
1.3K viewsAug 23, 2024
YouTubeHealthTree Foundation
8:52
Mieloma multiplo avanzato, efficacia confermata per elranatamab, anch…
1.8K viewsJun 25, 2023
YouTubePharmaStarTV
7:19
What is Immunotherapy for Multiple Myeloma? Understanding Its Role …
3.4K viewsSep 12, 2024
YouTubeInternational Myeloma Foundation
See more videos
Static thumbnail place holder